Medable Newsroom

Medable is partnering with industry leader Masimo to bring best-in-class medical-grade wearable devices to clinical research.

‍

The Phase IV trial, funded by a top-10 global pharmaceutical company, had a narrow recruitment window to enroll patients suffering from Anemia in End Stage Kidney Disease (ESKD) across more than 40 dialysis centers, involving 476 site users.

‍

Medable announces results from a new research project with Duke University BASE Lab on enhanced electronic informed consent (eIC) in clinical trials.

‍

Mohammed Ali of Medable: “Reapplying learnings to spark change and achieve scalability”

“The COVID-19 pandemic provided new impetus for creativity in clinical research, following several decades with little major disruption,” says Mohammed Ali, Chief Domain Expert at Medable. “Now we need to persevere to build on this momentum and move forward, applying pandemic learnings to create sustainable approaches.”

‍

What was your background prior to this role, and how did it prepare you for the work you do now? I learned a lot of the key qualities of being a CEO from team sports and my experience conducting research at Stanford. It was the perfect combination that directly applies to leading the team at Medable, with a strong focus on our mission to get effective therapies to patients faster, plus the relentless drive and working as a team to reach our goals.

As the industry moves from a study-by-study DCT implementation approach to a scalable enterprise-wide digital model, DCTs will help drive cycle time reduction and cost efficiencies while supporting the identification of life-changing new compounds.

By Sanskriti (“Sans”) Thakur, CGO. As we celebrate Women’s History Month this March, the world takes a moment to recognise women’s accomplishments, while also highlighting the inequity that remains. When it comes to women’s health, those inequities are stark. And a contributing factor is the lack of women in clinical trials. When population representation falls short, medicines are less safe and effective. Measures such as the US Congress’s proposed DIVERSE Trials Act are helping drive equitable representation, but that’s just the beginning.

By Hady Khoury, Chief Development Officer, Medable. The life sciences industry has been talking about improving diversity in clinical trials for years. Historically, this talk has amounted to a lot of hot air. But the situation is urgent: while racial and ethnic minorities comprise nearly 40% of the US population, they only account for 2% to 16% of clinical trial participation. Within oncology, Black Americans constitute around 22% of cancer cases, but less than 5% of trial enrollees. This isn’t just a US issue; globally, 76% of patients enrolled in oncology trials are white. And this challenge exists within a research landscape where nearly 80% of trials fall short of enrollment targets to begin with.

‍

‍

By Ingrid Oakley-Girvan, PhD, SVP, Value and Strategy. As decentralized clinical trials (DCTs) become more prevalent, particularly in the wake of the pandemic, their lower burden approach can make participation more attractive for some. Yet the vexing issue of retaining participants throughout the course of a trial will continue to be problematic without a thoughtful approach to keep them engaged. A three-phase model of engagement, based on proven science and intelligently informed by utilizing data, can make important inroads into solving this long-standing challenge.